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Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128S126amyloidoma in 7 patients. AutoSCT was performed in 126
patients (PA¼79 and AM¼47).
Results: The day 100 NRM was 5% and 1-year NRM was 8%.
With a follow up of 14 years in surviving patients, the 10-year
overall survival (OS) of AL patients was signiﬁcantly better in
those undergoing AutoSCT (41% vs. 17%; p<0.0001; Figure 1).
Involvement of more than one organ (6-yr OS 36% vs. 55%;
p¼0.04) and cardiac involvement (2-yr OS of 57% vs. 78%;
p¼0.01) were associated with poor outcome. In the
patients undergoing AutoSCT: PA vs. AM, Mayo staging,
Boston University (BU) staging or bone marrow plasma
cells >10 % at the time of autoSCT did not have an impact
on OS. Cardiac biomarkers including NT-ProBNP and
Troponin-I and T levels were available in a limited number
of patients and were not analyzed for survival outcomes. In
multivariate analysis, superior OS was associated with: age
<60yrs (HR 2.1, p¼0.022); and induction treatment before
AutoSCT (HR 2.7, p¼0.02). Involvement of kidney as the
only end organ showed a trend toward improved survival
(HR 1.6, p¼0.06). Speciﬁcally for PA patients (n¼79);
treatment before autoSCT was associated with improved 3-
yr OS: 85% vs. 66%; p¼0.02.
Figure 1. OS: AutoSCt vs. Conventional Therapy in AL Amyloidosis patients.
Conclusions: AL patients should be evaluated for AutoSCT
and selected patients should undergo induction therapy to
decrease amyloid burden prior to AutoSCT.
32
Are Outcomes After Myeloablative Conditioning Regimen
in Double Cord Blood Transplantation (UCBT) Better Than
Single UCBT for Adults with Acute Leukemia in
Remission?
Annalisa Ruggeri 1, Henrique Bittencourt 2, Guillermo Sanz 3,
Alessandro Rambaldi 4, Ibrahim Yakoub-Agha 5,
Josep-Maria Ribeira 6, William Arcese 7, Lionel Mannone 8,
Jorge Sierra 9, Carlos Solano 10, Samir Nabhan 1,
Luciana Tucunduva 1, Fernanda Volt 1, Chantal Kenzey 1,
Eliane Gluckman 11, Myriam Labopin 12, Vanderson Rocha 13.
1 Eurocord International Registry, Paris, France; 2 Hospital de
Clinicas, MG, Brazil; 3 Servicio de Hematologia, Hospital Univ.
La Fe, Valencia, Spain; 4 USC Hematology and Laboratory of Cell
Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy),
Bergamo, Italy; 5 CHU de Lille; 6 IJC-ICO Badalona, Hospital
Germans Trias i Pujol, Universitat Autònoma de Barcelona,Badalona; 7 Dipartimento di Biotechnology Cellurari e
Ematologia, University, Rome, Italy; 8 Service d’Hematologie,
CHU L’Archet; 9 Hematologia Clinica, Hospital de la Santa Creu i
Sant Pau, Barcelona, Spain; 10Hospital Clinico, Spain;
11Hospital Saint Louis, Eurocord, Paris, France; 12 Service
d’Hématologie et Thérapie Cellulaire, AP-HP, UPMC Université
Paris 6, UMR-S 938, CEREST-TC EBMT, Hôpital Saint Antoine;
13Haematology, Eurocord, Paris, France
Allogeneic hematopoietic stem cell transplantation
(HSCT) is indicated for patients (pts) with acute leukemia
(AL). For adults requiring HSCT urgently, such as pts in ﬁrst
complete remission (CR1), UCBT is a valid stem cells source.
With the aim to compare single vs double UCBTafterMACwe
analyzed 239 adults with AL in CR1. Pts were transplanted
with sUCBT (n¼156) or dUCBT (n¼83) from 2005-2011 in
EBMT centers for ALL (n¼101) and AML (n¼138). Type of
MACwas statistically associated with outcomes therefore pts
were analyzed in 3 different groups: Group 1: pts receiving
sUCBT with TBI-basedþCy (þFlu) (n¼68) (performed in 42
transplant centers (TC)), Group 2: pts receiving sUCBT with
BuþFluþThiotepa (n¼88) (performed in 23 TC) and Group 3:
pts receiving dUCBT with CyþTBIþFlu (n¼83) (performed in
47 TC). Median follow-up: 24 months. No statistical differ-
ences were found among the 3 groups for pts and disease
characteristics however pts in group2 were older than in
group1 and 3 (p¼0.03).
Median infused TNC was 2.9x107/kg for group1, 3x107/kg
for group2, and 3.7x107/kg for group3 (p¼0.01). ATG was
part of conditioning regimen in 73% of pts. The use of ATG
was different in the 3 groups (70%, 90% and 40% for group1, 2
and 3, respectively p<0.001).
For group1, group2 and group3, cumulative incidence (CI)
of 60 days neutrophil recovery was 82%, 89% and 87%
(p¼0.15), with median time of 27, 21 and 24 days, respec-
tively (p<0.001).
CI of acute GVHD (grade II-IV) was 30% vs 20% vs 45% for
group1, group2 and group3, respectively (p¼0.001). CI of
chronic GvHD at 1 year was 29%, no differences in CI among
the groups.
At 1 year, CI of TRM was 44% for group1, 33% for group2
and 36% for group3 (p¼0.46). In multivariate analysis, two
factors were associated with higher TRM: diagnosis of ALL
(p¼0.048) and age>35 years (p¼0.049). One-Hundred-six
pts died and causes of death were infection (n¼38), GvHD
(n¼18), other transplant-related-events (n¼31) or relapse
(n¼18).
CI of 2y relapse was 25% for group1, 18% for group2 and
16% for group3 (p¼0.22). No factors were found associated
with increase relapse incidence in multivariate analysis. The
2y probability of leukemia-free-survival (LFS) was 31% for
group1 (sUCBT-TBI based), 48% for group2 (sUCBT-BuFluTT),
and 47% for group3 (dUCBT) (p¼0.03). No center effect was
found. In multivariate analysis, use of sUCBT using TBI based
MAC (HR¼0.9, p¼0.003), diagnosis of ALL (HR¼0.69, p¼0.04)
and age>35years (HR¼1.4, p¼0.04) were independently
associated with decreased LFS.
In this registry based analysis, in the myeloablative
setting for adults with AL in CR1, outcomes (TRM, RI and LFS)
after dUCBT were not statistically different from sUCBT using
iv-BuFluTT. However, compared to sUCBT using TBI-based
MAC, dUCBT was associated with lower RI and better LFS
rates.
In the MAC setting, the combination of conditioning
regimens and type of graft (single vs. double) may have
different impact UCBT outcomes.
